StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2023, quý kết thúc ngày Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Endonovo Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Endonovo Therapeutics's operating income for the twelve months ending Sep 30, 2023 was -$2.62M. For fiscal 2022 it was -$3.26M. The highest annual figure on record is -$77.99K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$3.26M–
FY2021Dec 31, 2021-$2.23M–
FY2020Dec 31, 2020-$2.91M–
FY2019Dec 31, 2019-$3.81M–
FY2018Dec 31, 2018-$4.16M–
FY2017Dec 31, 2017-$4.60M–
FY2016Dec 31, 2016-$5.41M–
FY2015Dec 31, 2015-$2.56M–
FY2014Dec 31, 2014-$2.19M–
FY2013Dec 31, 2013-$2.43M–
FY2012Dec 31, 2012-$1.74M–
FY2011Dec 31, 2011-$95.52K–
FY2010Dec 31, 2010-$77.99K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2023Sep 30, 2023-$472.80K–
Q2 FY2023Jun 30, 2023-$1.13M–
Q1 FY2023Mar 31, 2023-$529.29K–
Q4 FY2022Dec 31, 2022-$483.05K–
Q3 FY2022Sep 30, 2022-$496.78K–
Q2 FY2022Jun 30, 2022-$1.80M–
Q1 FY2022Mar 31, 2022-$485.76K–
Q4 FY2021Dec 31, 2021-$373.79K–
Q3 FY2021Sep 30, 2021-$692.26K–
Q2 FY2021Jun 30, 2021-$570.05K–
Q1 FY2021Mar 31, 2021-$590.44K–
Q4 FY2020Dec 31, 2020-$683.96K–
Q3 FY2020Sep 30, 2020-$946.80K–
Q2 FY2020Jun 30, 2020-$601.83K–
Q1 FY2020Mar 31, 2020-$679.61K–
Q4 FY2019Dec 31, 2019-$730.00K–
Q3 FY2019Sep 30, 2019-$1.29M–
Q2 FY2019Jun 30, 2019-$974.82K–
Q1 FY2019Mar 31, 2019-$813.00K–
Q4 FY2018Dec 31, 2018-$1.03M–
Q3 FY2018Sep 30, 2018-$1.04M–
Q2 FY2018Jun 30, 2018-$816.66K–
Q1 FY2018Mar 31, 2018-$1.28M–
Q4 FY2017Dec 31, 2017-$832.96K–
Q3 FY2017Sep 30, 2017-$1.04M–
Q2 FY2017Jun 30, 2017-$2.18M–
Q1 FY2017Mar 31, 2017-$557.51K–
Q4 FY2016Dec 31, 2016-$632.81K–
Q1 FY2016Jun 30, 2016-$3.47M–
Q1 FY2015Mar 31, 2015-$431.63K–
Q4 FY2014Dec 31, 2014-$170.55K–
Q3 FY2014Sep 30, 2014-$627.18K–
Q2 FY2014Jun 30, 2014-$826.36K–
Q1 FY2014Mar 31, 2014-$567.12K–
Q4 FY2013Dec 31, 2013-$493.98K–
Q3 FY2013Sep 30, 2013-$427.82K–
Q2 FY2013Jun 30, 2013-$481.60K–
Q1 FY2013Mar 31, 2013-$1.03M–

More Endonovo Therapeutics figures

See a number that looks wrong?